adamantane has been researched along with Obesity in 45 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (8.89) | 29.6817 |
| 2010's | 36 (80.00) | 24.3611 |
| 2020's | 5 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, CG; Jing, CB; Liu, DW; Liu, X; Lu, Q; Wang, H; Wang, Q; Xiong, WY; Xu, G; Yang, L; Ye, YS | 1 |
| Aerts, JMFG; Boot, R; Foppen, E; Herrera Moro Chao, D; Jansen, K; Kalsbeek, A; Kooijman, S; Marques, AR; Mergen, C; Mirzaian, M; Ottenhoff, R; Overkleeft, H; Parlevliet, ET; Rensen, PCN; Scheij, S; Seeley, RJ; Tschöp, MH; van Eijk, M; van Roomen, C; Verhoek, M; Wang, D; Wang, Y; Yi, CX | 1 |
| Bermudez Saint Andre, K; Coverdale, S; Dursteler, A; Gutierrez, AD; Hamidi, V; Miller Iii, C; Riggs, K; Taegtmeyer, H; Wang, H; Westby, C; Zhu, L | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Chunchai, T; Jaiwongkam, T; Kerdphoo, S; Pratchayasakul, W; Saiyasit, N; Sripetchwandee, J | 1 |
| Chiheb, S; Cosson, E; Fysekidis, M; Rezki, A; Valensi, P; Vicaut, E | 2 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Jiang, C; Li, X; Liang, G; Sa-Nguanmoo, P; Tanajak, P; Wang, X | 1 |
| Chen, Q; Huang, L; Kong, L; Wang, J; Wang, Z; Xu, D; Zhang, T; Zhou, X | 1 |
| Cheng, F; Guo, X; He, J; Yuan, G; Zhang, J | 1 |
| Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Kerdphoo, S; Pratchayasakul, W; Sa-Nguanmoo, P; Tanajak, P | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, S; Ittichaicharoen, J; Sa-Nguanmoo, P; Tanajak, P | 1 |
| Cavadas, C; Cunha-Santos, J; Leal, H; Marques, AP; Pereira de Almeida, L; Rosmaninho-Salgado, J; Sousa-Ferreira, L | 1 |
| Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Jiang, C; Kerdphoo, S; Li, X; Liang, G; Pratchayasakul, W; Sa-Nguanmoo, P; Tanajak, P; Wang, X | 1 |
| D'Souza, K; Koska, J; Meyer, C; Osredkar, T; Reaven, PD; Sands, M; Sinha, S; Zhang, W | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Pintana, H | 2 |
| García-Ortega, YE; Gómez-Gaitán, EA; González-Ortiz, LJ; González-Ortiz, M; Martínez-Abundis, E; Pérez-Rubio, KG; Robles-Cervantes, JA; Sánchez-Peña, MJ | 1 |
| Ahrén, B; Ekblad, E; Foley, JE; Omar, BA; Vikman, J; Voss, U; Winzell, MS | 1 |
| Chatterjee, S | 1 |
| Ishibashi, Y; Maeda, S; Matsui, T; Nakashima, S; Nishino, Y; Ojima, A; Yamagishi, S; Yamakawa, R; Yoshida, Y | 1 |
| Del Prato, S; Foley, JE; Kothny, W; Kozlovski, P; Matthews, DR; Paldánius, PM; Stumvoll, M | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, S; Chinda, K; Palee, S | 1 |
| Iwamura, T; Kainoh, M; Kawai, K; Kumagai, H; Nakaki, J; Nitta, A; Okazaki, S; Sakami, S; Sato, M; Sekiya, Y; Takahashi, T; Yagi, M | 1 |
| Chiamvimonvat, N; Despa, F; Despa, S; Dong, H; Hammock, BD; Harris, TR; Li, N; Margulies, KB; Sharma, S; Taegtmeyer, H | 1 |
| Chattipakorn, N; Chattipakorn, SC; Pipatpiboon, N; Pratchayasakul, W; Sripetchwandee, J | 1 |
| Cho, MH; Jang, JE; Kim, AR; Kim, BJ; Kim, H; Kim, HJ; Kim, JH; Kim, MO; Kim, SJ; Ko, MS; Koh, EH; Lee, KU; Leem, J; Oh, JS; Park, HS; Woo, CY; Yoo, HJ | 1 |
| Chattipakorn, N; Chattipakorn, SC; Pintana, H; Pongkan, W; Pratchayasakul, W | 1 |
| Ahn, JH; Bae, MA; Han, SJ; Kim, D; Kim, JY; Kim, KY; Kwak, HJ; Lee, DH; Lee, GB; Pagire, HS; Pagire, SH; Park, MJ; Rhee, SD; Ryu, JI; Song, JS | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC | 1 |
| Bugáňová, M; Haluzík, M; Holubová, M; Kaválková, P; Kuneš, J; Kuzma, M; Maletínská, L; Pelantová, H; Šedivá, B; Sýkora, D; Železná, B; Zemenová, J | 1 |
| Chattipakorn, N; Chattipakorn, SC; Pongkan, W; Pratchayasakul, W; Sa-Nguanmoo, P; Sivasinprasasn, S | 1 |
| Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Kredphoo, S; Pintana, H; Pongkan, W; Sivasinprasasn, S | 1 |
| Chattipakorn, N; Chattipakorn, SC; Pongkan, W; Pratchayasakul, W; Sivasinprasasn, S; Tanajak, P | 1 |
| Aerts, JM; Aten, J; Bijl, N; Boot, RG; Claessen, N; Groen, AK; Langeveld, M; Moerland, PD; Ottenhoff, R; Sokolović, M; van Eijk, M; van Roomen, CP; Vrins, C | 1 |
| Kuritzky, L | 1 |
| Anandan, SK; Chen, D; Gless, RD; MacIntyre, DE; Rubanyi, GM; Vincelette, J; Wang, YX; Webb, HK; Zhang, LN | 1 |
| Aavula, BR; Anandan, SK; Cases, S; Chen, D; Cheng, Y; Do, ZN; Gless, R; Hammock, BD; Jones, PD; MacIntyre, DE; Mehra, U; Patel, DV; Sabry, J; Tran, V; Vincelette, J; Wang, YX; Waszczuk, J; Webb, HK; Whitcomb, R; White, K; Wong, KR; Zhang, LN | 1 |
| Matsui, T; Nishino, Y; Takeuchi, M; Yamagishi, S | 1 |
| Bellamine, A; Jacob, RF; Jacoby, A; Kubant, R; Malinski, T; Mason, RP; Mizuno, Y; Walter, MF | 1 |
| Aerts, JM; Bijl, N; Bijland, S; Groen, AK; Houben-Weerts, JH; Houten, SM; Langeveld, M; Ottenhoff, R; Romijn, JA; van den Berg, SA; van Dijk, KW; van Roomen, CP; Voshol, PJ | 1 |
| Aerts, JM; Aten, J; Bietrix, FM; Bijl, N; Boot, RG; Dekker, N; Groen, AK; Groener, J; Langeveld, M; Lombardo, E; Ottenhoff, R; Overkleeft, HS; Serlie, M; van Eijk, M; van Roomen, C; Wennekes, T | 1 |
| Ahn, JH; Jung, WH; Kang, NS; Kang, SK; Kim, HY; Kim, KY; Park, JS; Rhee, SD | 1 |
| Golozoubova, V; Gotfredsen, CF; Knudsen, LB; Raun, K; Rolin, B; von Voss, P | 1 |
| Baig, MR; Balas, B; Cusi, K; Darland, C; Deacon, CF; DeFronzo, RA; Dunning, BE; Foley, JE; He, YL; Holst, JJ; Ligueros-Saylan, M; Mari, A; Wang, Y; Watson, C | 1 |
| Falck, JR; Hammock, BD; Huang, H; Morisseau, C; Wang, J; Wang, MH; Yang, T | 1 |
2 review(s) available for adamantane and Obesity
| Article | Year |
|---|---|
Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Obesity; Patient Compliance; Peptides; Piperidines; Precision Medicine; Primary Health Care; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2010 |
Glycosphingolipids and insulin resistance.
Topics: 1-Deoxynojirimycin; Adamantane; Animals; Cardiovascular Diseases; Ceramides; Diabetes Mellitus, Type 2; Dioxanes; Disease Models, Animal; Fatty Acids; Fatty Liver; Gaucher Disease; Glucosyltransferases; Glycosphingolipids; Humans; Insulin Resistance; Metabolic Syndrome; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Pyrrolidines; Receptor, Insulin; Signal Transduction | 2011 |
8 trial(s) available for adamantane and Obesity
| Article | Year |
|---|---|
Acute Exenatide Therapy Attenuates Postprandial Vasodilation in Humans with Prediabetes: A Randomized Controlled Trial.
Topics: Adamantane; Adult; Aged; Biomarkers; Blood Glucose; Cross-Over Studies; Dietary Fats; Dipeptides; Double-Blind Method; Exenatide; Female; Forearm; Humans; Incretins; Insulin; Lipids; Male; Middle Aged; Obesity; Postprandial Period; Prediabetic State; Texas; Time Factors; Treatment Outcome; Vasodilation | 2020 |
Acute and long-term effects of saxagliptin on post-prandial glycemic response in obese patients with impaired glucose tolerance.
Topics: Adamantane; Adult; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; France; Glucose Intolerance; Humans; Male; Middle Aged; Obesity; Pilot Projects; Postprandial Period; Time Factors; Treatment Outcome | 2021 |
Acute and long-term effects of saxagliptin on a set of cardiovascular targets measured at fasting and post-prandially in obese patients with impaired glucose tolerance: A placebo-controlled study.
Topics: Adamantane; Adult; Biomarkers; Blood Glucose; Cardiovascular System; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; France; Glucose Intolerance; Humans; Male; Middle Aged; Obesity; Pilot Projects; Postprandial Period; Time Factors; Treatment Outcome; Vagus Nerve | 2021 |
Effects of saxagliptin on glucose homeostasis and body composition of obese patients with newly diagnosed pre-diabetes.
Topics: Adamantane; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucose Intolerance; Homeostasis; Humans; Insulin Resistance; Life Style; Male; Metformin; Middle Aged; Obesity; Postprandial Period; Prediabetic State; Treatment Outcome | 2017 |
Effects of saxagliptin on adipose tissue inflammation and vascular function in overweight and obese people: a placebo-controlled study.
Topics: Adamantane; Adipose Tissue; Adult; Aged; Blood Glucose; Cells, Cultured; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Endothelial Cells; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Immunohistochemistry; Inflammation; Male; Middle Aged; Obesity; Overweight; Postprandial Period; Treatment Outcome | 2019 |
Effect of vildagliptin on glucose and insulin concentrations during a 24-hour period in type 2 diabetes patients with different ranges of baseline hemoglobin A1c levels.
Topics: Adamantane; Adult; Blood Glucose; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Insulin; Insulin Secretion; Insulin-Secreting Cells; Kinetics; Male; Middle Aged; Nitriles; Obesity; Overweight; Pyrrolidines; Vildagliptin | 2013 |
Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial.
Topics: Adamantane; Adolescent; Adult; Aged; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Intention to Treat Analysis; Metformin; Middle Aged; Nitriles; Obesity; Overweight; Pyrrolidines; Research Design; Vildagliptin; Young Adult | 2014 |
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.
Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Enzyme Inhibitors; Female; Glucose; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Islets of Langerhans; Kinetics; Male; Middle Aged; Nitriles; Obesity; Pyrrolidines; Vildagliptin | 2007 |
35 other study(ies) available for adamantane and Obesity
| Article | Year |
|---|---|
Sampsonione F suppresses adipogenesis via activating p53 pathway during the mitotic clonal expansion progression of adipocyte differentiation.
Topics: 3T3-L1 Cells; Adamantane; Adipocytes; Adipogenesis; Animals; Cell Differentiation; Mice; Mitosis; Obesity; Phytochemicals; Tumor Suppressor Protein p53 | 2022 |
The Iminosugar AMP-DNM Improves Satiety and Activates Brown Adipose Tissue Through GLP1.
Topics: 1-Deoxynojirimycin; Adamantane; Adipose Tissue, Brown; Animals; Brain; Glucagon-Like Peptide 1; Glucose; Male; Mice; Mice, Inbred C57BL; Obesity; Rats; Rats, Wistar; Satiation; Signal Transduction | 2019 |
Neurotensin receptor 1 agonist provides neuroprotection in pre-diabetic rats.
Topics: Adamantane; Animals; Cognitive Dysfunction; Diet, High-Fat; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hippocampus; Ileum; Imidazoles; Insulin Resistance; Male; Neuronal Plasticity; Obesity; Oligopeptides; Oxidative Stress; Prediabetic State; Random Allocation; Rats, Wistar; Receptors, Neurotensin | 2021 |
Comparisons of cardioprotective efficacy between fibroblast growth factor 21 and dipeptidyl peptidase-4 inhibitor in prediabetic rats.
Topics: Adamantane; Animals; Cardiotonic Agents; Diabetic Cardiomyopathies; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Fibroblast Growth Factors; Gene Expression Regulation; Heart Rate; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Mitochondria, Heart; Nitriles; Obesity; Prediabetic State; Pyrrolidines; Rats; Rats, Wistar; Recombinant Proteins; Tumor Necrosis Factor-alpha; Ventricular Dysfunction, Left; Vildagliptin | 2017 |
Mast Cell and M1 Macrophage Infiltration and Local Pro-Inflammatory Factors Were Attenuated with Incretin-Based Therapies in Obesity-Related Glomerulopathy.
Topics: Adamantane; Albuminuria; Animals; Creatinine; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucose Tolerance Test; Incretins; Inflammation; Interleukin-6; Kidney Diseases; Kidney Glomerulus; Liraglutide; Macrophages; Male; Mast Cells; Nitriles; Obesity; Pyrrolidines; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha; Vildagliptin | 2017 |
SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.
Topics: Adamantane; Animals; Anti-Inflammatory Agents; Apoptosis; Benzhydryl Compounds; Brain; Cognition Disorders; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Insulin; Insulin Resistance; Long-Term Potentiation; Male; Malondialdehyde; Maze Learning; Membrane Potential, Mitochondrial; Memory; Mitochondria; Neuroprotective Agents; Nitriles; Obesity; Oxidative Stress; Pyrrolidines; Rats, Wistar; Reactive Oxygen Species; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vildagliptin | 2017 |
Dipeptidyl peptidase-4 inhibitor enhances restoration of salivary glands impaired by obese-insulin resistance.
Topics: Adamantane; Animals; Apoptosis; Blotting, Western; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Inflammation; Insulin Resistance; Male; Mitochondria; Nitriles; Obesity; Oxidative Stress; Pyrrolidines; Rats; Rats, Wistar; Salivary Glands; Vildagliptin | 2018 |
Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice.
Topics: 3T3-L1 Cells; Adamantane; Adipocytes; Adipose Tissue, White; Animals; Blood Glucose; Collagen; Diet, High-Fat; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Extracellular Matrix; Fibrosis; Hypolipidemic Agents; Leptin; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Neuropeptide Y; Nitriles; Obesity; Pyrrolidines; Receptors, Neuropeptide Y; RNA Interference; RNA, Small Interfering; Transforming Growth Factor beta1; Vildagliptin | 2018 |
FGF21 and DPP-4 inhibitor equally prevents cognitive decline in obese rats.
Topics: Adamantane; Animals; Apoptosis; Cognitive Dysfunction; Dipeptidyl-Peptidase IV Inhibitors; Fibroblast Growth Factors; Hippocampus; Humans; Insulin Resistance; Male; Malondialdehyde; Mitochondria; Neuronal Plasticity; Nitriles; Obesity; Oxidative Stress; Pyrrolidines; Rats, Wistar; Signal Transduction; Vildagliptin | 2018 |
Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats.
Topics: Adamantane; Animals; Blood Glucose; Blood Pressure; Body Weight; Cardiotonic Agents; Cholesterol; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Heart; Heart Rate; Insulin; Insulin Resistance; Male; Malondialdehyde; Membrane Potential, Mitochondrial; Mitochondria, Heart; Nitriles; Obesity; Oxidative Stress; Pyrazines; Pyrrolidines; Rats, Wistar; Reactive Oxygen Species; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats.
Topics: Adamantane; Animals; Behavior, Animal; Brain; Cognition Disorders; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Hippocampus; Insulin Resistance; Male; Maze Learning; Memory; Memory Disorders; Mitochondria; Nitriles; Obesity; Oxidative Stress; Pyrazines; Pyrrolidines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Female; Immunohistochemistry; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Nitriles; Obesity; Pyrrolidines; Vildagliptin | 2013 |
Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: an observational study.
Topics: Adamantane; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Fasting; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; India; Metformin; Nitriles; Obesity; Postprandial Period; Pyrrolidines; Retrospective Studies; Treatment Outcome; Vildagliptin | 2014 |
Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats.
Topics: Adamantane; Administration, Oral; Analysis of Variance; Animals; Biomarkers; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression Profiling; Male; Nitriles; Obesity; Pyrrolidines; Rats; Real-Time Polymerase Chain Reaction; Retina; Vildagliptin | 2013 |
Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats.
Topics: Adamantane; Animals; Arrhythmias, Cardiac; Calcium; Cardiotonic Agents; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Heart Rate; Insulin Resistance; Intracellular Space; Male; Metformin; Mitochondria; Myocardial Ischemia; Myocardial Reperfusion Injury; Nitriles; Obesity; Pyrrolidines; Rats; Rats, Wistar; Ventricular Dysfunction, Left; Vildagliptin | 2014 |
HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Administration, Oral; Animals; Azepines; Carbenoxolone; Diabetes Mellitus, Experimental; Enzyme Inhibitors; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver; Obesity; Pioglitazone; Thiazolidinediones; Triazoles | 2014 |
Cardioprotection by controlling hyperamylinemia in a "humanized" diabetic rat model.
Topics: Adamantane; Animals; Animals, Genetically Modified; Calcium; Cardiomegaly; Diabetes Mellitus, Type 2; Disease Models, Animal; Eicosanoids; Epoxide Hydrolases; Heart; Humans; Insulin-Secreting Cells; Islet Amyloid Polypeptide; Myocardium; Myocytes, Cardiac; Obesity; Oxidative Stress; Pancreas; Prediabetic State; Rats; Sarcolemma; Urea | 2014 |
DPP-4 inhibitor and PPARγ agonist restore the loss of CA1 dendritic spines in obese insulin-resistant rats.
Topics: Adamantane; Animals; Blood Glucose; Cholesterol; Dendritic Spines; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Hippocampus; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Neuroprotective Agents; Nitriles; Obesity; Pioglitazone; PPAR gamma; Pyrrolidines; Rats; Rats, Wistar; Receptor, Insulin; Thiazolidinediones; Vildagliptin | 2014 |
11β-HSD1 reduces metabolic efficacy and adiponectin synthesis in hypertrophic adipocytes.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3-L1 Cells; Adamantane; Adiponectin; Adipose Tissue, White; Animals; Energy Metabolism; Enzyme Inhibitors; Gene Expression Regulation; Glycolysis; Hypertrophy; Lipid Metabolism; Lipotropic Agents; Liver; Male; Mice; Mice, Mutant Strains; Mitochondrial Dynamics; Niacinamide; Non-alcoholic Fatty Liver Disease; Obesity; Oxygen Consumption | 2015 |
Dipeptidyl peptidase 4 inhibitor improves brain insulin sensitivity, but fails to prevent cognitive impairment in orchiectomy obese rats.
Topics: Adamantane; Animals; Brain; Cognition; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Insulin Resistance; Male; Maze Learning; Mitochondria; Neuronal Plasticity; Nitriles; Obesity; Orchiectomy; Pyrrolidines; Rats; Rats, Wistar; Vildagliptin | 2015 |
Discovery and optimization of adamantane carboxylic acid derivatives as potent diacylglycerol acyltransferase 1 inhibitors for the potential treatment of obesity and diabetes.
Topics: Adamantane; Animals; Diabetes Mellitus, Experimental; Diacylglycerol O-Acyltransferase; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Humans; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Obesity; Structure-Activity Relationship; Zebrafish | 2015 |
Dipeptidyl peptidase-4 inhibitors and the ischemic heart: Additional benefits beyond glycemic control.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Insulin Resistance; Myocardial Ischemia; Nitriles; Obesity; Oxidative Stress; Pyrrolidines; Rats; Sitagliptin Phosphate; Ventricular Function, Left; Vildagliptin | 2016 |
Urinary metabolomic profiling in mice with diet-induced obesity and type 2 diabetes mellitus after treatment with metformin, vildagliptin and their combination.
Topics: Adamantane; Animals; beta-Alanine; Diabetes Mellitus, Type 2; Diet; Glucose Tolerance Test; Hypoglycemic Agents; Male; Metabolomics; Metformin; Mice; Mice, Inbred C57BL; Nitriles; Obesity; Pyridones; Pyrrolidines; Vildagliptin | 2016 |
Estrogen and DPP4 inhibitor, but not metformin, exert cardioprotection via attenuating cardiac mitochondrial dysfunction in obese insulin-resistant and estrogen-deprived female rats.
Topics: Adamantane; Animals; Cardiotonic Agents; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Estrogens; Female; Heart Rate; Hypoglycemic Agents; Insulin Resistance; Menopause, Premature; Metformin; Mitochondria, Heart; Nitriles; Obesity; Ovariectomy; Oxidative Stress; Pyrrolidines; Rats; Rats, Wistar; Vildagliptin | 2016 |
Vildagliptin reduces cardiac ischemic-reperfusion injury in obese orchiectomized rats.
Topics: Adamantane; Androgens; Animals; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Heart; Heart Rate; Insulin Resistance; Male; Mitochondria, Heart; Myocardial Reperfusion Injury; Nitriles; Obesity; Orchiectomy; Pyrrolidines; Rats; Rats, Wistar; Testosterone; Ventricular Function, Left; Vildagliptin | 2016 |
DPP-4 Inhibitor and Estrogen Share Similar Efficacy Against Cardiac Ischemic-Reperfusion Injury in Obese-Insulin Resistant and Estrogen-Deprived Female Rats.
Topics: Adamantane; Animals; Apoptosis; Blood Glucose; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Estradiol; Fasting; Female; Heart Rate; Insulin Resistance; Myocardial Reperfusion Injury; Myocardium; Myocytes, Cardiac; Nitriles; Obesity; Ovariectomy; Pyrrolidines; Rats; Rats, Wistar; Stroke Volume; Ventricular Function, Left; Vildagliptin | 2017 |
Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice.
Topics: 1-Deoxynojirimycin; Adamantane; Animals; Disease Models, Animal; Fatty Liver; Glucose; Glycosphingolipids; Homeostasis; Insulin; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Triglycerides | 2009 |
Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension.
Topics: Adamantane; Administration, Oral; Animals; Aorta; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Endothelium, Vascular; Epoxide Hydrolases; Hypertension; Male; Mesenteric Arteries; Mice; Mice, Inbred C57BL; Niacinamide; Obesity; Phenylurea Compounds; Rats; Rats, Sprague-Dawley; Urea; Vasodilation | 2011 |
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
Topics: Adamantane; Administration, Oral; Angiotensin II; Animals; Antihypertensive Agents; Blood Glucose; Disease Models, Animal; Enzyme Inhibitors; Epoxide Hydrolases; Hypertension; Insulin Resistance; Mice; Obesity; Rats; Urea | 2011 |
Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis.
Topics: Adamantane; Animals; Aorta, Thoracic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycation End Products, Advanced; Male; Nitriles; Obesity; Pyrrolidines; Rats; Rats, Inbred OLETF; Vascular System Injuries; Vildagliptin | 2011 |
Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats.
Topics: Adamantane; Animals; Aorta; Blood Glucose; CD40 Antigens; Cholesterol; Citrulline; Dipeptides; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Nitric Oxide Synthase Type III; Obesity; Rats; Rats, Zucker; Triglycerides | 2011 |
Treatment of genetically obese mice with the iminosugar N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin reduces body weight by decreasing food intake and increasing fat oxidation.
Topics: 1-Deoxynojirimycin; Adamantane; Adipose Tissue; Animals; Body Weight; Carbohydrate Metabolism; Carnitine O-Palmitoyltransferase; Eating; Ghrelin; Glucose; Imino Sugars; Liver; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Oxidation-Reduction; Peptide YY; Triglycerides; Up-Regulation; Weight Gain | 2012 |
Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3-L1 Cells; Adamantane; Adipocytes; Adipogenesis; Adrenal Glands; Animals; Biomarkers; CHO Cells; Cricetinae; Cricetulus; Diet; Enzyme Inhibitors; Gene Expression Regulation; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Hypothalamo-Hypophyseal System; Insulin Resistance; Mice; Molecular Docking Simulation; Obesity; Protein Conformation; Thiadiazines | 2012 |
Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.
Topics: Adamantane; Animals; Body Composition; Body Weight; Candy; Energy Intake; Energy Metabolism; Glucagon-Like Peptide 1; Hypoglycemic Agents; Liraglutide; Nitriles; Obesity; Pancreas; Pyrrolidines; Rats; Rats, Sprague-Dawley; Vildagliptin | 2007 |
Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats.
Topics: 8,11,14-Eicosatrienoic Acid; Adamantane; Animals; Blood Pressure; Blotting, Western; Diet; Dietary Fats; Fenofibrate; Glomerular Filtration Rate; Hypertension, Renal; Hypolipidemic Agents; Immunohistochemistry; Kidney; Lauric Acids; Male; Obesity; Rats; Rats, Sprague-Dawley; Renal Circulation; Sodium; Vascular Resistance; Water-Electrolyte Balance | 2007 |